Literature DB >> 28858993

PharmGKB summary: very important pharmacogene information for ABCG2.

Alison E Fohner1, Deanna J Brackman, Kathleen M Giacomini, Russ B Altman, Teri E Klein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28858993      PMCID： PMC5788016          DOI： 10.1097/FPC.0000000000000305

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN： 1744-6872            Impact factor:   2.089


× No keyword cloud information.
  122 in total

1.  ABCG2 null alleles define the Jr(a-) blood group phenotype.

Authors:  Teresa Zelinski; Gail Coghlan; Xiao-Qing Liu; Marion E Reid
Journal:  Nat Genet       Date:  2012-01-15       Impact factor: 38.330

2.  Hyperuricaemia: contributions of urate transporter ABCG2 and the fractional renal clearance of urate.

Authors:  Diluk R W Kannangara; Amanda J Phipps-Green; Nicola Dalbeth; Lisa K Stamp; Kenneth M Williams; Garry G Graham; Richard O Day; Tony R Merriman
Journal:  Ann Rheum Dis       Date:  2015-12-01       Impact factor: 19.103

3.  Functional analysis of SNPs variants of BCRP/ABCG2.

Authors:  Chihiro Kondo; Hiroshi Suzuki; Masaya Itoda; Shogo Ozawa; Jun-ichi Sawada; Daisuke Kobayashi; Ichiro Ieiri; Kazunori Mine; Kenji Ohtsubo; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2004-10       Impact factor: 4.200

Review 4.  ABC multidrug transporters: structure, function and role in chemoresistance.

Authors:  Frances J Sharom
Journal:  Pharmacogenomics       Date:  2008-01       Impact factor: 2.533

5.  Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry.

Authors:  N A Dobbs; C J Twelves; H Gillies; C A James; P G Harper; R D Rubens
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 6.  Pharmacogenomics of MRP transporters (ABCC1-5) and BCRP (ABCG2).

Authors:  Ulrike Gradhand; Richard B Kim
Journal:  Drug Metab Rev       Date:  2008       Impact factor: 4.518

Review 7.  ABC transporter regulation by signaling at the blood-brain barrier: relevance to pharmacology.

Authors:  David S Miller
Journal:  Adv Pharmacol       Date:  2014-08-22

8.  Cholesterol potentiates ABCG2 activity in a heterologous expression system: improved in vitro model to study function of human ABCG2.

Authors:  A Pál; D Méhn; E Molnár; S Gedey; P Mészáros; T Nagy; H Glavinas; T Janáky; O von Richter; G Báthori; L Szente; P Krajcsi
Journal:  J Pharmacol Exp Ther       Date:  2007-03-08       Impact factor: 4.030

9.  Single-nucleotide polymorphisms of ABCG2 increase the efficacy of tyrosine kinase inhibitors in the K562 chronic myeloid leukemia cell line.

Authors:  Karin Skoglund; Samuel Boiso Moreno; Jan-Ingvar Jönsson; Svante Vikingsson; Björn Carlsson; Henrik Gréen
Journal:  Pharmacogenet Genomics       Date:  2014-01       Impact factor: 2.089

10.  Tariquidar and elacridar are dose-dependently transported by P-glycoprotein and Bcrp at the blood-brain barrier: a small-animal positron emission tomography and in vitro study.

Authors:  Jens P Bankstahl; Marion Bankstahl; Kerstin Römermann; Thomas Wanek; Johann Stanek; Albert D Windhorst; Maren Fedrowitz; Thomas Erker; Markus Müller; Wolfgang Löscher; Oliver Langer; Claudia Kuntner
Journal:  Drug Metab Dispos       Date:  2013-01-10       Impact factor: 3.922
View more
  7 in total

Review 1.  ABC transporter superfamily. An updated overview, relevance in cancer multidrug resistance and perspectives with personalized medicine.

Authors:  Pérez-De Marcos Juan-Carlos; Pérez-Pineda Perla-Lidia; Méndez-Morales Stephanie-Talia; Arellano-Mendoza Mónica-Griselda; Torres-Espíndola Luz-María
Journal:  Mol Biol Rep       Date:  2021-02-22       Impact factor: 2.316

2.  Genetic factors in treatment-related cardiovascular complications in survivors of childhood acute lymphoblastic leukemia.

Authors:  Kateryna Petrykey; Aziz M Rezgui; Mathilde Le Guern; Patrick Beaulieu; Pascal St-Onge; Simon Drouin; Laurence Bertout; Fan Wang; Jessica L Baedke; Yutaka Yasui; Melissa M Hudson; Marie-Josée Raboisson; Caroline Laverdière; Daniel Sinnett; Gregor U Andelfinger; Maja Krajinovic
Journal:  Pharmacogenomics       Date:  2021-09-10       Impact factor: 2.638

Review 3.  Role of Genetic Variations in the Hepatic Handling of Drugs.

Authors:  Jose J G Marin; Maria A Serrano; Maria J Monte; Anabel Sanchez-Martin; Alvaro G Temprano; Oscar Briz; Marta R Romero
Journal:  Int J Mol Sci       Date:  2020-04-20       Impact factor: 5.923

4.  Genetic polymorphisms analysis of pharmacogenomic VIP variants in Bai ethnic group from China.

Authors:  Wanlu Chen; Heng Ding; Yujing Cheng; Qi Li; Run Dai; Xin Yang; Chan Zhang
Journal:  Mol Genet Genomic Med       Date:  2019-07-30       Impact factor: 2.183

Review 5.  Pharmacogenetics of Statin-Induced Myotoxicity.

Authors:  Ping Siu Kee; Paul Ken Leong Chin; Martin A Kennedy; Simran D S Maggo
Journal:  Front Genet       Date:  2020-10-16       Impact factor: 4.599

6.  ABCB1 and ABCG2 Together Limit the Distribution of ABCB1/ABCG2 Substrates to the Human Retina and the ABCG2 Single Nucleotide Polymorphism Q141K (c.421C> A) May Lead to Increased Drug Exposure.

Authors:  Myriam El Biali; Rudolf Karch; Cécile Philippe; Helmuth Haslacher; Nicolas Tournier; Marcus Hacker; Markus Zeitlinger; Doreen Schmidl; Oliver Langer; Martin Bauer
Journal:  Front Pharmacol       Date:  2021-06-16       Impact factor: 5.810

7.  Oxypurinol pharmacokinetics and pharmacodynamics in healthy volunteers: Influence of BCRP Q141K polymorphism and patient characteristics.

Authors:  Bianca Vora; Deanna J Brackman; Ling Zou; Maria Garcia-Cremades; Marina Sirota; Radojka M Savic; Kathleen M Giacomini
Journal:  Clin Transl Sci       Date:  2021-05-01       Impact factor: 4.689
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.